{
  "docId": "019de070-dce8-70ee-8639-85282f075771",
  "docSlug": "622e4280fc41e900213786c9a95190a7",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 40,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "before_after",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a three-column layout to show the evolution from legacy product (Synagis) to clinical trial results (Phase IIb and Phase III) for nirsevimab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-dce8-70ee-8639-85282f075771/29",
  "deckHref": "/decks/019de070-dce8-70ee-8639-85282f075771",
  "deckJsonHref": "/decks/019de070-dce8-70ee-8639-85282f075771.json",
  "deckAnchorHref": "/decks/019de070-dce8-70ee-8639-85282f075771#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.38,
        "y": 0.515
      },
      "kind": "chart",
      "text": "Nirsevimab Phase IIb efficacy chart",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69fb3a4c-f988-45dc-aba6-286ca43acf62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.515
      },
      "kind": "chart",
      "text": "Synagis efficacy chart",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87f880b7-25a9-4a7b-84e2-b72bb4415052",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.95,
        "x": 0.03,
        "y": 0.34
      },
      "kind": "list",
      "text": "Synagis benefits and trial results for nirsevimab",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f26545ba-bc4c-4f64-a040-4f8f60030e09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. Children of premature birth... 2. Respiratory syncytial (virus)... 3. Population: healthy infants...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2eb5eed-2676-440b-8fdf-f618569dd0dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "First immunisation to show benefit in a general infant population",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb1916fe-26d2-432a-bbf3-6803d80c1ac8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Respiratory & Immunology: nirsevimab",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb7ee87e-0c65-4515-85bc-a27623ea79b1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "c058c077-3012-4a40-973e-53fdee78619c",
      "evidence": "Compares legacy Synagis performance with new nirsevimab clinical data.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 29,
      "from": 29,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "3b0ed0fe-d45a-46d4-a9dc-61ab9c863fcd",
      "evidence": "The before-after loop is used to show progress",
      "position": 0,
      "objective": "Highlighting progress in Respiratory & Immunology",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}